AGAlberto Garrido-García

Alberto Garrido-García

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alberto Garrido-García has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Resistance of E2F4DN to p38 MAPK phosphorylation attenuates DNA damage-induced neuronal death via Cited2

    by Aina Maria Llabres-Mas, Noelia López-Sánchez, Alberto Garrido-García, Vanesa Cano-Daganzo, José M. Frade

    E2F4 is a transcription factor that supports cellular homeostasis and serves as a substrate for the stress-activated kinase p38 MAPK , which phosphorylates it at a conserved Thr248/Thr250 motif. A non-phosphorylatable mutant, E2F4DN (Thr248Ala/Thr250Ala), has shown therapeutic efficacy in a murine model of Alzheimer’s disease (AD). We hypothesized that phosphorylation of E2F4 disrupts its protective function, whereas E2F4DN retains this activity during cellular stress. To test this hypothesis, we treated N2a-derived neurons with camptothecin (CPT) to induce genotoxic stress. CPT activated p38 MAPK within 8 hours, leading to E2F4 phosphorylation at the Thr248/Thr250 site. We then overexpressed E2F4DN or a phosphomimetic variant, E2F4CA (Thr248Glu/Thr250Glu), and assessed apoptosis by procaspase-3 cleavage. E2F1, used as a pro-apoptotic control, strongly induced caspase-3 activation. This effect was partially mimicked by E2F4CA, whereas E2F4DN markedly suppressed caspase-3 cleavage. Notably, E2F4DN but not E2F4CA upregulated the antiapoptotic factor Cited2, and Cited2 knockdown abolished the protective effect of E2F4DN. These findings suggest that p38 MAPK -mediated phosphorylation of E2F4 promotes neuronal apoptosis, while E2F4DN maintains homeostatic function via Cited2, offering mechanistic insight into its neuroprotective role in AD.


  • Open Access

    The Alzheimer multifactorial therapeutic agent E2F4DN prevents long‐term potentiation and cognitive loss and improves neuronal survival in homozygous 5xFAD mice

    by Crisitna Sanchez‐Puelles, Alberto Fraj, Vanesa Cano‐Daganzo, Alberto Garrido‐García, Gertrudis Perea, Jose María Frade

    Background: Despite many decades of work, we still lack effective therapies against Alzheimer’s disease (AD), likely due to its complex etiology, which requires a multifactorial therapeutic approach. Among the variety of proposed etiological factors, synaptic failure has proof to be an early hallmarks of AD (Nat. Neurosci. 2016;19:443‐453), which precedes neuronal‐death (J. Neurosci. 2006;26:10129‐10140). We have recently shown, using both transgenic mice and gene therapy, that E2F4 is a multifactorial therapeutic target against AD (Neurotherapeutics 2021;18:2484‐2503, Mol. Neurobiol. 2022;59:3016‐3039), likely due to its homeostatic function (Int. J. Mol. Sci. 2022;23:12093). The phosphorylation of two conserved Thr residues of E2F4 is necessary to induce cognitive loss in AD (Neurotherapeutics 2021;18:2484‐2503). Therefore, we have developed a novel therapy consisting in neuronal expression of a dominant negative form of E2F4 (E2F4DN), which cannot be phosphorylated in the conserved Thr residues (Neurotherapeutics 2021;18:2484‐2503, Mol. Neurobiol. 2022;59:3016‐3039). In this work we wanted to verify whether the expression of E2F4DN could correct AD‐associated synaptic dysfunction and neuronal loss in 5xFAD mice, a known mouse model of AD.Method: We expressed E2F4DN (intravenous administration of AAV‐E2F4DN) in 6 weeks old control and homozygous 5xFAD mice, and stereological, electrophysiological and behavioral studies were performed at 6 months. Cell counting was achieved by unbiased stereology in the CA1 hippocampal region. Cognition was analyzed through novel‐object location and contextual fear conditioning test. Synaptic function (basal synaptic transmission, presynaptic function and long‐term potentiation (LTP)) were measured by electrophysiological recordings of field excitatory postsynaptic potentials in hippocampal CA3‐CA1 synapses. Afterwards, the mechanism underlying memory recovery was evaluated analyzing protein levels of different subunits of the synaptic receptors AMPA and NMDA.Result: E2F4DN expression in neurons prevents neuronal death in the hippocampus (CA1) of homozygous 5xFAD mice, reaching similar values of cell number and CA1 volume to those observed in control mice. Moreover, E2F4DN prevents LTP loss leading to cognitive improvement, as 5xFAD mice treated with our therapy present a noticeable improvement hippocampal‐dependent memory. This effect correlates with the increase of key LTP regulators.Conclusion: E2F4‐Based Gene Therapy improves neuronal survival, LTP and cognition, being a safe multifactorial approach for AD treatment.

  • Open Access

    A Mutant Variant of E2F4 Triggers Multifactorial Therapeutic Effects in 5xFAD Mice

    by Noelia López-Sánchez, Morgan Ramón-Landreau, Cristina Trujillo, Alberto Garrido-García, José M. Frade

    Alzheimer’s disease (AD) has a complex etiology, which requires a multifactorial approach for an efficient treatment. We have focused on E2 factor 4 (E2F4), a transcription factor that regulates cell quiescence and tissue homeostasis, controls gene networks affected in AD, and is upregulated in the brains of Alzheimer’s patients and of APPswe/PS1dE9 and 5xFAD transgenic mice. E2F4 contains an evolutionarily conserved Thr-motif that, when phosphorylated, modulates its activity, thus constituting a potential target for intervention. In this study, we generated a knock-in mouse strain with neuronal expression of a mouse E2F4 variant lacking this Thr-motif (E2F4DN), which was mated with 5xFAD mice. Here, we show that neuronal expression of E2F4DN in 5xFAD mice potentiates a transcriptional program consistent with the attenuation of the immune response and brain homeostasis. This correlates with reduced microgliosis and astrogliosis, modulation of amyloid-β peptide proteostasis, and blocking of neuronal tetraploidization. Moreover, E2F4DN prevents cognitive impairment and body weight loss, a known somatic alteration associated with AD. We also show that our finding is significant for AD, since E2F4 is expressed in cortical neurons from Alzheimer patients in association with Thr-specific phosphorylation, as evidenced by an anti-E2F4/anti-phosphoThr proximity ligation assay. We propose E2F4DN-based gene therapy as a promising multifactorial approach against AD.


  • Open Access

    E2F4-Based Gene Therapy Mitigates the Phenotype of the Alzheimer's Disease Mouse Model 5xFAD

    by Noelia López-Sánchez, Alberto Garrido-García, Morgan Ramón-Landreau, Vanesa Cano-Daganzo, José M. Frade